Jefferies trimmed its price target on ISIS Pharmaceuticals (NASDAQ: ISIS) from $10 to $8 and kept its Underperform rating despite ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE